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Abstract
Increased expression of Bcl-xL in cancer has been shown to confer resistance to a broad range of apoptotic stimuli and to
modulate a number of other aspects of cellular physiology, including energy metabolism, cell cycle, autophagy,
mitochondrial fission/fusion and cellular adhesion. However, only few of these activities have a mechanistic explanation.
Here we used Tandem Affinity purification to identify novel Bcl-xL interacting proteins that could explain the pleiotropic
effects of Bcl-xL overexpression. Among the several proteins co-purifying with Bcl-xL, we focused on Praf2, a protein with a
predicted role in trafficking. The interaction of Praf2 with Bcl-xL was found to be dependent on the transmembrane domain
of Bcl-xL. We found that Bcl-2 also interacts with Praf2 and that Bcl-xL and Bcl-2 can interact also with Arl6IP5, an
homologue of Praf2. Interestingly, overexpression of Praf2 results in the translocation of Bax to mitochondria and the
induction of apoptotic cell death. Praf2 dependent cell death is prevented by the co-transfection of Bcl-xL but not by its
transmembrane domain deleted mutant. Accordingly, knock-down of Praf2 increases clonogenicity of U2OS cells following
etoposide treatment by reducing cell death. In conclusion a screen for Bcl-xL-interacting membrane proteins let us identify a
novel proapoptotic protein whose activity is strongly counteracted exclusively by membrane targeted Bcl-xL.
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Introduction
The acquired capability to escape apoptosis is required at
several steps during cancer development. Over-expression of the
Bcl-xL protein is known to confer resistance to a broad range of
potentially apoptotic stimuli arising during cancer development,
such as oncogene activation, hypoxia and matrix detachment [1–
3]. Impaired apoptosis due to the over-expression of the Bcl-xL
gene is therefore critical during cancer progression. Impaired
apoptosis is also a major barrier to effective cancer treatment,
because cytotoxic therapies for cancer strongly rely on induction of
apoptosis. Interestingly, Bcl-xL has been suggested to play a
unique role in general resistance to cytotoxic agents, because of a
striking correlation between an increased Bcl-xL expression level
and resistance to a wide panel of standard chemotherapy agents.
Bcl-xL’s mechanism of action is therefore a major component of
chemoresistance in cancer cells [4]. Bcl-xL belongs to the Bcl-2
family of proteins whose members can have either anti-apoptotic
or pro-apoptotic functions. The proapoptotic members of the Bcl-
2 family fall into two subsets. The so-called multidomain factors
(Bax and Bak) are proteins sharing more than one Bcl-2 Homology
(BH) domain. The other subfamily comprises proteins sharing only
the BH3 domain. A picture has emerged suggesting that ‘‘BH3
only’’ proteins have diverse mechanisms of regulation and are
targeted sensors of different sources of cell stress. Their primary
function appears to be the binding and neutralization of the anti-
apoptotic Bcl-2 family membres [5], although some of them have
also been reported to be able to directly activate multidomain
proapoptotic family members [6,7]. It is therefore widely accepted
that elevated Bcl-xL protein level decreases susceptibility to
apoptosis because it increases the cellular potential to inactivate
pro-apoptotic ‘‘BH3 only’’ proteins [8].
Besides its ability to inhibit the core apoptotic machinery, Bcl-
xL has been shown to modulate a number of other aspects of
cellular physiology. Its overexpression, for instance, has been
correlated with high tumour grade and increased ability to invade
and metastasize, independently of its ability to sustain survival in
the absence of matrix attachment [9–11]. Bcl-xL has been found
to complement S.cerevisiae genes that facilitate the switch from
glycolytic to oxidative metabolism [12]. Bcl-xL is also able to
modulate calcium homeostasis [13], stimulate synapse formation
[14], slow cell cycle progression [15], modulate autophagy [16,17],
increase mitochondrial fission/fusion [18] and modulate metab-
olite exchange across the outer mitochondrial membrane [19].
Some of these ‘‘unconventional’’ Bcl-xL activities could be
explained by its ability to interact with proteins other than the
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15636pro-apoptotic ‘‘BH3 only’’ factors. Bcl-xL has indeed been shown
to interact with VDAC1 [20], with the IP3 Receptor [21], with
Beclin1 [22] and a number of other proteins.
Bcl-xL is both a cytosolic and a membrane-associated protein
[23]. While cytosolic Bcl-xL appears to be a homodimer [24], the
quaternary structure of membrane-bound Bcl-xL has not been
investigated in details, although it has been reported that it could
be engaged in high molecular weight complexes [25] (Borner
personal communication). In the present study we present
evidence that Bcl-xL is indeed part of high molecular weight
complexes and we attempt to carry a comprehensive analysis of
proteins able to bind Bcl-xL using Tandem Affinity Purification.
Interestingly, we found that Bcl-xL interacts with proteins involved
in several cellular processes. Among them, the secretory pathway
was one of the most represented pathways. With the aim of
validating the list of proteins found to interact with Bcl-xL, we
decided to focus our analysis on the interaction between Bcl-xL
and Praf2, a small protein belonging to the Prenylated Rab
Acceptor family, with a predicted role in ER to Golgi transport
[26]. We show that Praf2 induces apoptotic cell death upon
expression and that Bcl-xL counteracts Praf2’s apoptotic activity.
Finally, we show that Praf2 silencing in U2OS cells makes them
more resistant to apoptosis induced by the cytotoxic drug
etoposide.
Results
To investigate the possibility that Bcl-xL is associated with
membrane proteins in high molecular weight complexes, we have
used sucrose gradient fractionations of CHAPS-solubilized whole
cells extracts. The analysis was performed using the U2OS cell line
because it expresses high levels of Bcl-xL and appears to be
‘‘addicted’’ to Bcl-xL expression for survival (not shown). Pre-
cleared cell extracts were loaded on sucrose gradients and
subjected to ultracentrifugation as specified in Materials and
Methods. Fractions were collected, resolved by SDS-PAGE and
analysed by immunoblot. Figure 1 shows that low molecular
weight proteins like Cytochrome c (12 kDa), Rab 4 (25 kDa) or
Bax (20 kDa) are present in fractions of the gradient where low-
molecular weight proteins are expected to sediment. Bcl-xL,
instead, is spread in fractions ranging from low to high molecular
weights. This result suggests that under these experimental
conditions Bcl-xL could be engaged in a number of different
molecular complexes.
Establishment of HeLa cells expressing a TAP-Bcl-xL
chimera protein
In order to identify the set of proteins interacting with Bcl-xL in
the conditions analysed, we made use of Tandem Affinity
Purification [27,28]. Bcl-xL is a tail-anchored protein that acquires
membrane localisation inserting its C-terminal hydrophobic tail
into the lipid bilayer of several membrane compartments. To
avoid interference with Bcl-xL membrane insertion, we generated
an expressing vector placing a TAP tag at the N-terminus of Bcl-
xL. We also obtained a control vector where a Stop codon was
added downstream of the TAP sequence. Both constructs were
transfected in HeLa cells to obtain clones stably expressing either
TAP-Bcl-xL or TAP-stop only. We chose HeLa cells because they
can easily be adapted to growth in suspension cultures, in order to
produce starting material suitable for biochemical purifications.
Unlike U2OS, HeLa cells, furthermore, have a relatively low
expression level of endogenous Bcl-xL (Figure S1), which may
compete with TAP-Bcl-xL for binding partners. To test if the
addition of the TAP tag to Bcl-xL could impair its ability to protect
from apoptosis, we challenged cells expressing TAP-Bcl-xL
(HeLa/TAP-Bcl-xL) or TAP-stop (HeLa/TAP) with UV irradia-
tion and analysed the cleavage status of PARP, as a measure of
cellular caspase 3 activity. As shown in Figure 2A, compared to
TAP-stop, HeLa expressing TAP-Bcl-xL displayed a reduced level
of the PARP cleavage product. Therefore, addition of the TAP tag
to the N-terminus of Bcl-xL does not prevent the ability of Bcl-xL
to protect cells from UV-induced apoptosis. We next tested if the
addition of the TAP tag to Bcl-xL could alter its subcellular
distribution. HeLa/TAP-Bcl-xL cells were fractionated in cytosolic
(S100), nuclear (Nuclei), heavy membranes (HMM) and light
membranes (LMM) fractions by differential centrifugation.
Subcellular localisation of TAP-Bcl-xL compared to endogenous
Bcl-xL was analysed by immunoblot. The analysis has been
performed using equivalent amounts of proteins for each given
fraction and it is not informative on relative distribution of the
proteins analysed in the different cellular compartments. The
quality of the fractionation was defined using antibodies against
known markers of subcellular compartments: PARP for the
nuclear fraction, Sec23 for the LMM fraction (microsomes) and
Cytochrome c for the HMM fraction (mitochondria). We also
analysed the localisation of Bax, another member of the Bcl-xL
protein family, that is known to localise both at the mitochondria
an in the cytosol. Figure 2B shows that, similarly to endogenous
Bcl-xL, TAP-Bcl-xL localises to the HMM fraction, to the LMM
and to the S100 fractions. Therefore, addition of the TAP tag does
not interfere with the ability of Bcl-xL to acquire membrane
localisation.
Identification of novel Bcl-xL-interacting proteins using
Tandem Affinity Purification
In order to produce a suitable starting material for TAP
purifications, HeLa/TAP-Bcl-xL and HeLa/TAP cells were
adapted to growth in suspension culture using spinning glass
bottles. Given our interest in membrane based interactions we
chose to focus on purifications performed using membrane
extracts. Cell pellets were mechanically lysed using a Dounce
homogeniser in a detergent-free hypotonic buffer. Centrifugation
of the latter cell lysate allowed us to separate total membranes
from cytosolic proteins. Total membranes were extracted using a
CHAPS containing buffer, and subjected to tandem affinity
purification. Eluates from the last purification step were concen-
trated and resolved on SDS-PAGE. Fig. 2C shows representative
pictures of TAP purifications analysed on Coomassie stained gels
Figure 1. Bcl-xL is present in a wide range of molecular weights
in fractionated U2OS cell extracts. Sucrose gradient fractionation
of U2OS total cell extracts. U2OS (60610
6 cells) were lysed in CHAPS
extraction buffer and cleared by centrifugation. Extracts were fraction-
ated using a 10–40% sucrose gradient and equal volumes of the
fractions were analysed by immunoblot for the presence of Bcl-xL, Bax,
Rab4 and Cytochrome c.
doi:10.1371/journal.pone.0015636.g001
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cells (lane 2). Little material arose from the purifications made
from TAP only expressing cells, indicating that the background
given by unspecific adsorption to the chromatographic media used
is negligible. Bands corresponding to the most abundant protein
species were cut from the gels and their identity was assessed by
LC-MS/MS. A list of protein found to co-elute with TAP-Bcl-xL
is shown in Table 1.
Bcl-xL is able to interact with proteins involved in several
cellular processes
Although the list of Bcl-xL interacting proteins presented in
Table 1 cannot be taken as exhaustive, it can be considered a high
confidence list. We have subdivided all identified proteins in
different functional categories and for each protein we have
specified the known or putative sub-cellular localisation. We have
also stated if the protein had already been previously found to
interact with Bcl-xL. It is interesting to note that most of anti-
apoptotic members of the Bcl-2 protein family that have been
previously described to interact with Bcl-xL are present in the final
eluate. VDAC1 was also already described to interact with Bcl-xL
[20], while VDAC2, a less abundant isoform, has been shown to
interact with the multidomain Bcl-2 family member Bak [29].
ATP2A2/Serca2 instead, has been reported to interact with Bcl-2
[30]. Overall the presence of these proteins in the final eluate of
our purification constitutes a good indication of the specificity of
the interactions found. Besides the Bcl-2 family members, we put
together a group of proteins that are all mitochondrial and are
functionally involved in energy metabolism and mitochondrial
physiology. This group includes 10 of the 17 subunits of the ATP
Synthase multiprotein complex, subunits II and IV of the
cytochrome c oxidase and cytochrome b5 type B, all part of the
biochemical chain responsible for oxidative phosphorylation and
ATP production. It also includes mitochondrial carbamoyl-
phosphate synthetase 1, which plays an important role in
removing excess ammonia from the cell, and VDAC1 and 2,
main regulators of mitochondrial permeability. In this group we
included two more mitochondrial proteins identified as Bcl-xL
associated: Stomatin-like protein 2 (StomL2) and Prohibitin 2.
StomL2 has been recently shown to be part of a complex with
Mitofusin 2 [31] while Prohibitin 2 is supposed to play a role in the
regulation of mitochondrial respiration.
Another set of proteins could be grouped in the functional
category of transporters. They are located at different membrane
compartments, and are: the amino acid transporter SLC3A2; the
cell membrane Na+/K+ transporter ATPase ATP1A1; the ER
resident calcium transporter ATPase ATP2A2/Serca2; the
transferrin receptor, that could be seen as an atypical transporter.
Figure 2. TAP-Bcl-xL is able to protect from apoptosis, localise correctly and co-purify with several cellular proteins. (A) HeLa cells
stably expressing TAP-tagged Bcl-xL are more resistant than control to UV-induced apoptosis. Analysis of PARP cleavage in HeLa cells expressing TAP
alone or TAP-Bcl-xL and irradiated or not with UV (200 J/m
2). Cells were collected 2 and 4 hours after irradiation and analysed by immunoblot for the
appearance of the cleaved product of PARP. (B) TAP-tagged Bcl-xL localises to the same intracellular compartment of endogenous Bcl-xL. HeLa cells
expressing TAP-Bcl-xL were fractionated by differential centrifugation to obtain: lane 1, cytosolic proteins (S100); lane 2, nuclear proteins (Nuclei); lane
3, the heavy membrane fraction (HMM); lane 4, the light membrane fraction (LMM). 20 mg of each fraction were analysed by immunoblot for the
presence of TAP-BclxL (using secondary antibody only) and endogenous Bcl-xL. The quality of the fractionation was determined using the antibodies
against Sec23 (LMM), Cytochrome c (HMM), Bax (S100 and HMM) and PARP (Nuclei). (C) HeLa cells stably transfected with TAP alone or TAP-Bcl-xL
were subjected to Tandem Affinity Purification. The figure shows a representative Coomassie stained SDS-PAGE performed under reducing
conditions used to resolve eluates from purifications. Purifications were performed using membrane CHAPS extracts from HeLa expressing TAP alone
(lane 1) or HeLa expressing TAP-Bcl-xL (lane 2).
doi:10.1371/journal.pone.0015636.g002
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Name Description Gene Bank UniProt Loc Known
Bcl-2 family members
Bad BCL2-associated agonist of cell death NP_004313 Q92934 Cyto/Mito 3
Bax BCL2-associated X protein NP_004315 Q07812 Cyto/Mito/ER 3
Bak BCL2-antagonist/killer 1 NP_001179 Q16611 Mito/ER 3
Bid BH3 interacting domain death agonist NP_932070 P55957 Cyto/Mito 3
BBC3 BCL2 binding component 3 NP_001120713 Q9BXH1 Cyto/Mito 3
Bim BCL2-like 11 (apoptosis facilitator) NP_619527 O43521 Cyto/Mito 3
Mitochondrial energy metabolism and physiology
ATP5A1 ATP synthase alpha subunit NP_004037 P25705 Mito
ATP5B ATP synthase beta subunit NP_001677 P06576 Mito
ATP5O ATP synthase OSCP subunit NP_001688 P48047 Mito
ATP5D ATP synthase delta subunit NP_001678 P30049 Mito
ATP5F1 ATP synthase b subunit NP_001679 P24539 Mito
ATP5J2 ATP synthase f subunit NP_001003713 P56134 Mito
ATP5L ATP synthase g subunit NP_006467 O75964 Mito
ATP5I ATP synthase e subunit NP_009031 P56385 Mito
ATP5H ATP synthase d subunit NP_001003785 O75947 Mito
ATP5C1 ATP synthase gamma chain NP_001001973 P36542 Mito
MT-CO2 Cytochrome c oxidase Subunit II NP_536846 P00403 Mito
COX4I1 Cytochrome c oxidase Subunit IV NP_001852 P13073 Mito
CYB5B Cytochrome b5 type B NP_085056 O43169 Mito
CPS1 Carbamoyl phosphate synthetase 1 NP_001116105 P31327 Mito
VDAC1 Voltage-dependent anion channel 1 NP_003365 P21796 Mito 3
VDAC2 Voltage-dependent anion channel 2 NP_003366 P45880 Mito
PHB2 Prohibitin 2 NP_001138303 Q99623 Mito
STOML2 stomatin (EPB72)-like 2 NP_038470 Q9UJZ1 Mito
Transporters
SLC3A2 Solute carrier family 3, member 2 NP_001012679 P08195 MEM
ATP1A1 ATPase, Na+/K+ transporting, alpha 1 subunit NP_000692 P05023 MEM
ATP2A2 ATPase, Ca++ transporting, SERCA2 NP_733765 P16615 ER 3
TFRC Transferrin receptor NP_001121620 P02786 MEM
Trafficking
SEC61B SEC61 beta subunit NP_006799 P60468 ER
SEC11A SEC11 homolog A NP_776890 P67810 ER
CANX Calnexin NP_001737 P27824 ER
MPDU1 Manose-P-dolichol utilization defect 1 NP_004861 O75352 ER
RPN1 Ribophorin I NP_002941 P04843 ER
DDOST dolichyl-diphosphooligosaccharide-protein glycosyltransferase NP_005207 P39656.3 ER
SEC22B Vesicle trafficking protein sec22b NP_004883 O75396 ER
TMED10 transmembrane emp24-like protein 10 NP_006818 P49755 Golgi
ERGIC1 ER-Golgi intermediate compartment 1 NP_001026881 Q969X5 Golgi/ER
TMED5 Transmembrane emp24 protein transport domain containing 5 NP_057124 Q9Y3A6 Golgi/ER
Praf2 PRA1 domain family, member 2 NP_009144 O60831 ER
KDELR1 KDEL endoplasmic reticulum protein retention receptor 1 NP_006792 P24390 ER
SSR4 Signal sequence receptor delta NP_006271 P51571 ER
RAB7A RAB7A, member RAS oncogene family NP_004628 P51149 Endo
VAMP3 Vesicle associated membrane protein 3 NP_004772 Q6FGG2 Endo
Unknown
IFITM1 Interferon induced transmembrane protein 1 NP_003632 P13164 MEM
C8orf55 Mesenchymal stem cell protein DSCD75 NP_057731 Q8WUY1 Sec
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associated with Bcl-xL is composed of proteins with a putative
or established role in the secretory branch of intracellular
trafficking. Those are components of the translocation complex
(Sec61 beta, Sec11A), chaperones involved in protein folding
assistance in the ER (Calnexin), proteins involved in ER specific
protein modifications (Ribophorin I, OST48, MPDU1) and
proteins with a putative role in ER to Golgi trasport (Sec22b,
ERGIC-32, TMP21, TMED5, Praf2) as well as ER retention
(SSR4, KDEL receptor 1). Other trafficking proteins associated
with Bcl-xL were Rab7, a small GTPase with a role in late
endosome maturation and VAMP3, a protein with a putative role
in endosomes recycling. Finally we identified as novel Bc-xL
interacting proteins a group of factors either with unknown or very
poorly described function (Table 1).
Validation of the interaction between Praf2 and Bcl-xL
The relationship between the secretory branch of intracellular
trafficking and apoptotic cell death is far from being understood.
Among the newly identified proteins, Praf2 has been suggested to
play a role in ER to Golgi transport [26]. Praf2 belongs to the
Prenylated Rab Acceptor (PRA) family of proteins, whose founder,
Pra1/Rabac1, has been shown to interact with the viral Bcl-2
homologue BHRF1, and modulate its activity [32]. To gain
insights into the relationship between vesicular transport and
apoptosis, we decided to focus our attention on Praf2. The cDNA
coding for human Praf2 was obtained from the IMAGE
consortium and cloned in pcDNA3 with a triple HA tag fused at
its C-terminus. In order to validate the interaction between Praf2
and Bcl-xL, 293T cells were transfected either with Praf2
HA and
FLAGBcl-xL expression plasmids alone or co-transfected with both
plasmids. 24 hours after transfections cells were lysed and Praf2
was immunoprecipitated using monoclonal anti-HA conjugated
agarose. As shown in Fig. 3A,
FLAGBcl-xL was detectable in the
precipitate only when co-expressed with Praf2. We were therefore
able to confirm the interaction of Bcl-xL and Praf2 also in a two-
components system, where Bcl-xL and Praf2 are concomitantly
overexpressed.
The finding that Praf2 co-purified with Bcl-xL by Tandem
Affinity Purification clearly demonstrates that Bcl-xL is able to
interact with endogenous Praf2 in HeLa cells. We now
investigated if endogenous Bcl-xL is able to interact with Praf2
in U2OS cells. U2OS cells were transfected either with empty
vector or with the Praf2
HA expressing vector, and lysates were
Name Description Gene Bank UniProt Loc Known
FAM162A E2-induced gene 5 protein NP_055182 Q96A26 Mito
SFXN1 Sideroflexin 1 NP_073591 Q9H9B4 Mito
TMEM109 Transmembrane protein 109 NP_076997 Q9BVC6 ER
UPF0569 Hypothetical protein LOC203547 NP_001017980 Q3ZAQ7 MEM
USMG5 Upregulated during skeletal muscle growth 5 NP_116136 Q96IX5 Mito
CISD2 CDGSH iron sulfur domain 2 NP_001008389 Q8N5K1 ER
LC-MS/MS identified proteins from TAP purifications performed on total membranes of TAP-Bcl-xL expressing HeLa cells were divided into the functional categories
described. The table provides name, description and accession numbers of the identified proteins. The table also states the subcellular localisation (known or putative)
of the proteins (Loc) and if the protein had already been found interacting with Bcl-xL (known). Mito: mitochondrial; ER: endoplasmic reticulum; MEM: plasma
membrane; Cyto: cytosolic; Sec: secreted.
doi:10.1371/journal.pone.0015636.t001
Table 1. Cont.
Figure 3. Bcl-xL and Praf2 interact by co-immunoprecipitation. (A) HEK 293T cells were either transfected with HA-tagged Praf2 or FLAG-
tagged BclxL or co-transfected with both expression vectors. Samples were subjected to immunoprecipitation, using anti HA-conjugated agarose and
both total lysates (inputs) and agarose beads eluates (IP) were analysed by immunoblot using anti HA and anti FLAG monoclonal antibodies. (B)
U2OS cells were transfected with HA-tagged Praf2 or the empty vector (Vec) and cell lysates were subjected to immunoprecipitation, using HA-
conjugated agarose. Both lysates and agarose beads were analysed by immunoblot using anti HA and anti Bcl-xL antibodies.
doi:10.1371/journal.pone.0015636.g003
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in Fig. 3B, anti HA-conjugated agarose can specifically precipitate
endogenous Bcl-xL in U2OS cells transfected with Praf2
HA but
not with the empty vector.
Multiple members of the Bcl-2 family are able to interact
with multiple members of the PRA family
The founder member of the PRA family of proteins, Pra1/
Rabac1, has been shown to interact with the viral Bcl-2
homologue BHRF1, but not with Bcl-2 itself [32]. We therefore
asked if the binding ability of Praf2 was limited to Bcl-xL or could
be extended to Bcl-2 as well. We also asked if the close homologue
of Praf2, Arl6IP5, is also able to interact with Bcl-xL and/or Bcl-2.
Fig. 4 shows that Praf2
HA can interact also with
FLAGBcl-2 (lane 4),
and also that, Arl6IP5
HA can interact with both
FLAGBcl-xL and
FLAGBcl-2 (lane 5 and 6). Arl6IP5
HA expression results in bands
with different electrophoretic mobility. Given that they are all
immunoprecipitated by the anti-HA antibody and given that it has
been described that both Praf2 and Arl6IP5 can give rise to SDS-
insoluble species [33], we believe the bands observed correspond
to monomers, dimers and multimers of Arl6IP5.
The transmembrane domain of Bcl-xL is essential for its
interaction with Praf2
The ability of Bcl-xL to interact with the pro-apoptotic
members of the Bcl-2 family is known to be mediated by a
hydrophobic cleft formed on its surface by the BH1, BH2 and
BH3 domains [34]. Conversely, the binding of Bcl-2/xL to Raf
and Ras has been shown to depend on the BH4 domain [35,36].
In order to define the domains of Bcl-xL responsible for its
interaction with Praf2, we generated a Bcl-xL mutant deleted of its
first 24 aminoacids corresponding to the BH4 domain (Bcl-
xLDBH4). We also generated a Bcl-xL mutant in which tyrosine
101 was replaced with a lysine (Bcl-xLY101K) (Fig. 5A), a
mutation that has been described to abolish Bcl-xL’s ability to
interact with Bax [37]. Finally, because Praf2 is a membrane
protein [33], we generated a Bcl-xL mutant deleted of its C-
terminal 22 aminoacids corresponding to its transmembrane
domain (Bcl-xLDTM). As shown in Fig. 5B, neither deletion of the
Figure 4. Praf2 and Arl6IP5 interact also with Bcl-2. HEK 293 cells
were either transfected with FLAG-tagged BclxL or Bcl-2 alone (lane 1
and 2), or co-transfected with HA-tagged Praf2 or HA-tagged Arl6IP5
(lanes 3 to 6). Samples were subjected to immunoprecipitation, using
HA-conjugated agarose and both lysates and agarose beads were
analysed by immunoblot using anti HA and anti FLAG antibodies.
Arl6IP5 monomer: *; Arl6IP5 dimer: **; Arl6IP5 multimer: ***.
doi:10.1371/journal.pone.0015636.g004
Figure 5. Deletion of Bcl-xL’s transmembrane domain prevents
its interaction with Praf2. (A) Schematic representation of the Bcl-xL
expression constructs used in this study. Bcl-xL: full length Bcl-xL; Bcl-
xLDBH4: Bcl-xL lacking the first 24 aminoacids; Bcl-xLDTM: Bcl-xL lacking
the last 22 aminoacids; Bcl-xLY101K: Bcl-xL with a substitution of
Tyrosine 101 with Lysine. (B) HEK 293 cells were co-transfected with HA-
tagged Praf2 and the BclxL constructs described in (A) carrying a FLAG-
tag at the N-terminus. Samples were subjected to immunoprecipitation,
using HA-conjugated agarose and both lysates and agarose beads were
analysed by immunoblot using anti HA and anti FLAG antibodies.
doi:10.1371/journal.pone.0015636.g005
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interact with Praf2. However, deletion of the C-terminal
transmembrane domain, completely abolished Praf2/Bcl-xL
interaction, indicating that the TM domain is essential to this
interaction.
Praf2 overexpression induces apoptotic cell death
It is widely accepted that elevated Bcl-xL protein levels decrease
susceptibility to apoptosis by binding and inactivating pro-
apoptotic proteins [8]. Furthermore it has been reported that
overexpression of Yip3p (yeast Pra1/Rabac1 homologue) severely
inhibited cell growth [38]. We therefore tested if Praf2
overexpression could induce cell death, and if this could be
blocked by the concomitant expression of Bcl-xL or the Bcl-
xLDTM mutant that was shown to be unable to bind to Praf2.
HeLa cells were transfected with vector alone, with Praf2 or co-
transfected with Praf2 and Bcl-xL or Praf2 and Bcl-xLDTM.
Fig. 6A shows that Praf2 transfection resulted in a strong induction
of cell death, with almost 65% of cells becoming PI positive.
Interestingly Praf2 induced cell death was completely inhibited by
the concomitant transfection of full length Bcl-xL, but no
inhibition was observed when Praf2 was cotransfected with the
Bcl-xLDTM mutant. Furthermore, cell death induced by Praf2 is
accompanied by caspase activation as assessed by appearance of
the cleaved form of PARP. Again, this phenomenon was
completely blocked by Bcl-xL but not by the Bcl-xLDTM mutant
(Fig. 6B). Inhibition of Praf2-induced PARP cleavage was also
prevented by the concomitant expression of Bcl-2 (data not
shown).
Next, we wanted to assess if Praf2-induced apoptosis involved
the translocation of Bax to the mitochondria, an early event in the
intrinsic apoptotic pathway. We therefore cotransfected a GFP-
Bax construct with Praf2 or vector control in U2OS. Fig. 6C
shows that GFP-Bax expression in U2OS cells can have either a
diffuse cytosolic staining, or can be aggregated in clusters. We have
previously shown that GFP-Bax aggregation, in the same cell line,
was coincident with mitochondrial dysfunction, as measured by a
loss of DYm [39]. We used an excess of Praf2-expressing or empty
(Vec) plasmids in order to obtain that all cells receiving GFP-Bax
also received Praf2 and counted the % of transfected cells with
diffused or aggregated GFP-Bax signal. The result presented in
Fig. 6C shows that Praf2 co-transfection was associated with more
than 30% of cells displaying a GFP-Bax aggregated staining,
respect to only 2% observed in empty-vector co-tansfected cells.
Knock-down of Praf2 increases cellular survival
We next wanted to define if reduction of Praf2 expression by
RNA interference could also influence cellular viability. The
osteosarcoma cell line U2OS expresses relatively high levels of
Praf2. We knocked-down Praf2 expression in U2OS cells using
two different siRNAs targeting different regions of human Praf2
mRNA. Western blot analysis of Praf2 shows a strong decrease in
Praf2 expression with respect to control-transfected cells (Fig. 7A).
No obvious morphological difference was discernible between
Figure 6. Expression of Praf2 induces apoptotic cell death. (A)
FACS analysis of HeLa cells transfected with the indicated expression
vectors and stained with Propidium Iodide (PI). Percentages of PI
positive cells are indicated on the top-left of each graph. (B) Aliquots of
the HeLa cells transfected as in (A) were analysed by immunoblot for
the appearance of the cleaved form of PARP. Expression levels of Praf2,
Bcl-xL and Bcl-xLDTM are also indicated. (C) Analysis of GFP-Bax
localisation in U2OS cells transfected with empty vector (vec) or HA-
tagged Praf2. The photographs are representative of the two main GFP-
Bax localisations observed in the samples: diffuse cytosolic and
aggregated. Above the photographs are indicated the % of GFP
positive cells with an aggregated localisation after transfecting cells
with empty vector or HA-tagged Praf2 in two independent experi-
ments.
doi:10.1371/journal.pone.0015636.g006
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normal growth conditions. We therefore asked if Praf2 silencing
could affect cellular sensibility to the toxic effect of a chemother-
apeutic agent like etoposide. As shown in Fig. 7B silencing of Praf2
with both the siRNAs chosen resulted in a reduction of more than
50% in caspase activation relative to control transfected cells.
Accordingly, clonogenicity of U2OS cells treated with etoposide
increased from below 20% of Ctrl transfected cells to almost 60%
in Praf2 silenced cells (Fig. 7C). The decrease in caspase activation
observed after Praf2 RNAi was not apoptotic stimulus-specific nor
cell type-specific, as it was evident also in U2OS cells treated with
paclitaxel or doxorubicin (Fig. S2A) and in the breast cancer cell
line MDA-MB 231 treated with etoposide (Fig. S2B).
Discussion
Bcl-xL is a C-tail anchored protein with the ability to localise on
several intracellular membranes. In order to have a wide picture of
the set of membrane proteins interacting with Bcl-xL, we
performed Tandem Affinity Purification from total cellular
membranes of HeLa cells stably expressing TAP-tagged Bcl-xL.
Given that nonionic detergents like Triton-100 or NP-40 are
known to alter the conformation of proteins of the Bcl-2 family
[23], all the experiments were performed in presence of CHAPS, a
detergent that leaves the conformation of Bcl-xL unchanged. As
listed in Table 1, we found many proteins co-purifying with TAP-
Bcl-xL. However, those are likely to reflect true protein-protein
interactions for at least two reasons. First of all, as shown in lane 1
of Fig. 2C, purifications from the same cell line carrying a TAP-
tag-only construct recover almost undetectable proteins, suggest-
ing that all recovered proteins are indeed associated to Bcl-xL.
Second, as discussed below, using this procedure we found co-
eluting with Bcl-xL many proteins known to be able to specifically
interact with Bcl-xL. We have sub-divided the list of proteins
found to interact with Bcl-xL into the functional categories
discussed below. It is worth to notice that all the proteins found are
either trans-membrane proteins or soluble proteins localised in
intracellular organelles. Most of them localise to the sub-cellular
compartments known to be targeted by Bcl-xL. Many of them are
multiple components of protein complexes. These observations
constitute a good indication of the validity of the approach used
and of the specificity and sensitivity of the technique used. We can
therefore draw the conclusion that Bcl-xL can be engaged in
several different protein complexes at several sub-cellular sites.
This conclusion is further supported by the sucrose gradient
fractionation data presented in Fig. 1, showing a spread distribu-
tion of Bcl-xL over a wide range of molecular weights, without
discrete peaks of sedimentation.
Bcl-2 family members
The list of proteins found to interact with Bcl-xL, shown in
Table 1, includes the multidomain Bcl-2 family members Bax and
Bak, together with the BH3-only proteins Bim, Puma, Bid and
Bad. Strikingly, these are exclusively members of the subset of
BH3-only proteins shown to have highest affinity for Bcl-xL in
recent binding studies [40]. The presence of Bax indicates that
perhaps mitochondrially localised Bax can be bound by Bcl-2 pro-
survival proteins in an analogous manner as that now demon-
strated conclusively for Bak [41]. BH3-only proteins are low
abundance proteins and of small molecular weight, therefore
making them difficult to detect by mass spectrometry. The fact
that these proteins were detected at levels allowing protein
sequencing, and in concordance with recently published literature,
indicates the purifications were working reliably and efficiently.
Figure 7. Praf2 knock down reduces apoptosis and increases
clonogenicity of U2OS cells treated with etoposide. (A)A n a l y s i s
by immunoblot of the efficacy of Praf2 knock down following
transfection of U2OS cells with two different siRNAs targeting the
Praf2 mRNA. (B) U2OS cells transfected with control (Ctrl) or Praf2
targeting siRNAs (siRNA5 and siRNA6) after 48 hours were treated
with 50 mM etoposide for 24 hours. Cellular caspase 3 and 7
activities were measured using the Caspase-Glo 3/7 luminometric
assay. The graph show the percentage of caspase 3 and 7 activation
in samples treated with the Praf2 targeting siRNAs compared with
the activity present in cells transfected with the control siRNA in 3
independent experiments. (C) Clonogenicity of U2OS cells trans-
fected with control or Praf2 targeting siRNAs and treated or not with
etoposide. 48 hours after transfection of U2OS cells with control
siRNA or Praf2 siRNA6, cells were treated with 50 mMe t o p o s i d ef o r
3 hours and than shifted again to normal medium for 2 weeks.
Colonies were colored using crystal violet. The graph represents the
percentage of colonies grown after etoposide treatment respect to
the untreated control.
doi:10.1371/journal.pone.0015636.g007
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The main mitochondrial protein complex co-purifying with Bcl-
xL was the F1F0 ATP Synthase complex. The F1F0 ATP Synthase
complex is a highly conserved enzyme complex catalysing the
terminal step in ATP synthesis. The mammalian complex contains
at least 17 subunits, 10 of which are present in the list of Bcl-xL
interactors (Table 1). The functional significance of a direct
biochemical interaction between Bcl-xL and the ATP Synthase is
presently unclear. It could be that what we observe is not a direct
interaction but is mediated by Bax, given that Bax is interacting
with Bcl-xL in our experimental setting, and given that the F1F0
ATP Synthase complex is found also to interact with Bax in TAP-
Bax purifications (J.R.C and J.D unpublished observations). It is
interesting to note that changes in DYm occurring at the time of
onset of apoptosis do not have a defined molecular mechanism. In
the absence of sufficient flux through the electron transport chain
hydrolysis of ATP via reversal of the F1F0 ATP Synthase could
provide an alternative mechanisms by which DYm can be
maintained. It is possible that Bax and Bcl-xL have as yet
undefined roles in coordinating (Bcl-xL) or disrupting (Bax) the
metabolic mechanisms by which ATP production and mainte-
nance of DYm are coordinated.
Trafficking and transporters
Our screen for Bcl-xL interacting proteins unexpectedly
revealed the ability of Bcl-xL to interact with several proteins
with a known or putative role in the secretory branch of
intracellular trafficking. Examples of possible connections between
protein secretion and apoptosis do exist in the literature. DAD1,
the smallest subunit of the Ribophorin/OST complex, catalysing
the first step in N-linked glycosylation of proteins, was named after
it was originally identified as Defender Against apoptotic cell
Death [42]. DAD1 has also been reported to interact with Mcl-1
in a yeast two hybrid assay [43]. These interactions may underly a
link between glycosylation defects and the initiation of apoptosis,
as suggested in the work of Hauptmann et al. [44]. The authors
report that inhibition of N-linked glycosylation in yeast results in a
range of phenotypes similar to those seen during apoptotic cell
death of mammalian cells, such as DNA fragmentation and
phosphatidylserine exposure, and these could be blocked by Bcl-2.
We speculate that the ability of Bcl-2/xL to counteract the loss of
viability due to glycosylation defects may be mediated by the novel
interactions we identified.
An ability of Bcl-xL to modulate the secretory pathway would fit
well with the view of Bcl-xL as a general guardian of cellular
viability. Often cellular receptors are able to transduce intracel-
lular survival signals and soluble secreted factors are mediators of
growth/survival signals. The same is true for nutrient transporters
that need to be heavily modified by the secretory pathway in order
to be correctly delivered to the membrane. Is worth to notice that
most of the transporters we found associated to Bcl-xL have been
previously implicated in the regulation of cellular viability. The
amino acid transporter SLC3A2, for instance, is a cell surface
protein that is also able to associate with integrins and to mediate
growth/survival signals [45]. Similarly, inhibition of the Na+/K+
transporter ATPase ATP1A1 was recently shown to induce
sensitization to anoikis in cancer cells [46]. In general it has been
demonstrated that, once on the membrane, nutrient transporters
increase cell viability in nutrients limiting conditions [47].
Interestingly the work of Erdinger et al. shows that an increased
persistence of nutrient transporters on the membrane can be
achieved also by inhibiting the activity of Rab7 with the
consequence of reducing endocytosis-associated transporter deg-
radation. Given that Rab7 is among the Bcl-xL interacting
proteins we have found (Table 1), we can speculate that Bcl-xL
could have evolved a complex strategy to increase cellular viability
at the membrane level: increase the efficiency of receptor/
transporter delivery to the membrane, acting on the secretory
pathway and decrease their turnover modulating Rab7 activity.
Finally, the interactions we found may also not be directly
related to the anti-apoptotic role of Bcl-xL. Recently several
reports have suggested a positive role for Bcl-xL in cellular
invasiveness and tumor metastasis, independent of its ability to
protect from cell death [9–11]. Modulation of the secretory
pathway could be related to adhesion, motility and invasion, given
that all the molecular players in these processes are either soluble
secreted proteins (chemokines) or membrane receptors that need
to be folded, modified and delivered by the secretory pathway.
Praf2
Given the presence of so many proteins with a role in the
secretory branch of intracellular trafficking, we decided to validate
the novel Bcl-xL interacting proteins found, focusing on Praf2, a
small transmembrane protein with a putative role in ER to Golgi
transport [26]. Praf2 belongs to the family of Prenylated Rab
Acceptor (PRA) proteins. Vertebrates have three PRA family
members, Rabac1, Praf2 and Arl6IP5. They are small trans-
membrane proteins located to the Golgi complex (Rabac1) [48]
and the Endoplasmic Reticulum (Praf2 and Arl6IP5) [33]. The
degree of sequence homology among the PRA proteins is stronger
between Praf2 and Arl6IP5 (45% of sequence identity) than
between Rabac1 and Praf2 (25% of sequence identity). The
cellular function of PRA proteins has not been univocally defined.
It has been suggested that Rabac1 could mediate loading of the
inactive-GDI-bound cytosolic pool of Rabs on intracellular
membranes, given its in vitro GDI displacement activity [49].
Surprisingly though, yeast mutants deleted of the yip3 gene
(S.cerevisiae Rabac1 homologue) did not show any changes in the
intracellular localization of Rabs. Instead a striking proliferation of
the ER membranes, accompanied by inhibition of cell growth, was
observed following yip3 overproduction [38].
Rabac1 has been shown to interact with BHRF1, a viral
homologue of Bcl-2. Interestingly the anti-apoptotic activity of
BHRF1 was reduced upon interaction with Rabac1 [32].
Furthermore it has been shown that Praf2 expression correlated
with cerulenin-induced apoptosis [50] and Arl6IP5 is a key
mediator of the apoptosis induced by C/EBPalpha [51]. We
speculated therefore that the interaction of Bcl-xL with Praf2
might constitute a link between the secretory and the apoptotic
pathways.
In this study, we have confirmed the ability of Praf2 to interact
with Bcl-xL and defined that the interaction depends on Bcl-xL’s
C-terminal transmembrane (TM) region. The dependency on the
TM region might be interpreted in different ways: either the TM
region is directly involved in the interaction or is a pre-requisite for
the interaction because it is the anchor that localises Bcl-xL on the
membrane were it can find its partner Praf2. Given that secondary
structure prediction algorithms suggest that Praf2 is almost entirely
embedded in the membrane bilayer, it is reasonable to think that
the interaction could be directly mediated by a hydrophobic
amino-acid stretch like the TM domain.
Unlike Bcl-2, that is predominantly located to the ER, Bcl-xL
has been suggested to be mainly a mitochondrial protein located at
the Mitochondrial Outer Membrane (MOM) [52]. Praf2, instead,
has been shown to be mainly located at the ER (data not shown
and [33]). How can two proteins located at different intracellular
compartments interact? In our cellular fractionation experiments
we can always observe a small fraction of Bcl-xL located to the
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One possibility is that the interaction is limited to the small
fraction of ER-based Bcl-xL. We do observe, in fact, a partial co-
localization between Bcl-xL and Praf2 particularly pronounced in
the cellular perinuclear region (Fig. S3). Another possibility is that
the localisation of one or both proteins is dynamic and the
interaction is limited to a particular physiological stage. It is known
for instance that Bcl-xL translocates from the cytosol to the
mitochondria following an apoptotic stimulus [23]. There could be
a yet undefined stimulus that induces Bcl-xL relocalisation mainly
to the ER. One can even hypothesize that Praf2 would function as
the receptor of Bcl-xL under such a condition. A final possibility is
that the most relevant physiological interaction occurs between
Praf2 and Bcl-2 (more than Bcl-xL), given that Bcl-2 localises
mainly to the ER [52]. We have indeed demonstrated that Praf2 is
able to interact with both Bcl-2 and Bcl-xL (Fig. 4).
Independently to which is the relevant physiological partner,
our study shows that modulation of Praf2 expression could affect
cellular viability. We found that overexpression of Praf2 induces
translocation and aggregation of Bax at the mitochondria and,
ultimately, increases cellular caspase activity and cell death (Fig. 6).
On the same track, reducing Praf2 expression by RNAi in the
U2OS osteosarcoma cell line, we observed an increased resistance
to cytotoxic effect of the chemotherapeutic drug etoposide (Fig. 7).
What could be the mechanism explaining Praf2’s proapoptotic
activity? And how to reconcile these data with the observation that
the expression of Praf2 in human tumor tissues is higher than in
normal tissues of the same patient? [53] Another group of ER
based proteins found to interact with Bcl-xL and/or Bcl-2 and to
modulate cell death is composed of members of the Reticulon
family of proteins: RTN1-C, RTN4A and RTN3. Interestingly the
yeast homologue of Praf2, Yip3p, has been found interacting with
the reticulon Rtn1p [38], and our preliminary results suggest that
Praf2 is also able to interact with RTN4 (data not shown). The
mechanism by which RTN proteins modulate sensitivity to
apoptosis is also not entirely clear but is supposed to be based
on the ability of RTN proteins to influence Bcl-xL/Bcl-2
subcellular localisation. RTN4 has been suggested to reduce the
antiapoptotic activity of Bcl-xL and Bcl-2 by forcing their
localisation onto the ER and reducing their presence on the
mitochondria [54]. RTN3, instead, was shown to be able to
increase the accumulation of Bcl-2 on mitochondria [55].
Interestingly, although RTN3 expression induces apoptosis, its
concomitant expression with Bcl-2 increases Bcl-2’s antiapoptotic
activity [56]. One possibilty is that Praf2 and RTN4 work in the
same multiprotein complex having the ability to define the
subcellular localisation of Bcl-2 proteins. In this scenario, the
consequences of Praf2 overexpression on cellular viability could
vary depending on the type of anti-apoptotic Bcl-2 protein
expressed and on their dependency for survival. We know for
instance that U2OS cells strongly rely on Blc-xL for survival,
because Bcl-xL RNAi in U2OS rapidily triggers apoptosis (data
not shown). If Praf2 would sequester a pool of cellular Bcl-xL on
the ER, the consequence of Praf2 RNAi in U2OS could be a shift
of the same pool to the mitochondria where it could contribute to
protection against apoptotic stimuli that trigger mitochondria
destabilization. This is exactly what we observe in U2OS cells
treated with etoposide (Fig. 7).
The possibility that Praf2, forming a complex with RTN
proteins could be able to potentiate the anti-apoptotic activity of
Bcl-2/xL, as shown for RTN3 [56], could also help to explain why
an increased Praf2 expression would be selected during tumor
formation. The negative effect of Praf2 on cellular viability would
be counterbalanced by the concomitant increase in cellular
survival potential once anti-apoptotic oncogenes like Bcl-2 and/
or Bcl-xL becomes activated.
Conclusions
In conclusion, we have identified a number of novel Bcl-xL
associated proteins involved in several biological processes. The
variety of proteins found to interact with Bcl-xL could explain the
pleiotropic effect of Bcl-xL overexpression. Characterisation of
Praf2, one of the novel Bcl-xL interacting proteins, revealed that
modulation of its expression could interfere with cellular sensitivity
to chemotherapy. We speculate therefore that some of the novel
interactions described here could be at the basis of the unique role
played by Bcl-xL in cellular resistance to cytotoxic agents.
Materials and Methods
Reagents and cell culture
U2OS and HEK 293T cells were described previously [28].
HeLa cells were obtained from Dr. MV Ursini (Institute of
Genetics and Biophysics). Etoposide, colloidal Coomassie, mono-
clonal anti-HA conjugated Agarose (clone HA-7) and monoclonal
anti Flag (M2) were from Sigma-Aldrich. Monoclonal antibodies
directed against PARP, Cytochrome c (7H8.2C12) and polyclonal
against Bcl-xL were from BD Biosciences, polyclonal against Rab4
was from Abcam, was from Sigma, monoclonal anti Bax (2D2),
polyclonal anti Sec23 (E19) and monoclonal anti HA (F7) were
purchased from Santa Cruz Biotechnology. An antibody against
Praf2 was obtained immunising rabbits with GST-tagged full-
length recombinant Praf2.
HeLa, U2OS and HEK 293T cells were cultured in Dulbecco’s
modified Eagle’s medium supplemented with 100 mg/ml strepto-
mycin, 100 units/ml penicillin, and 10% fetal bovine serum (FBS)
(pH 7.2–7.4) in a humidified atmosphere containing 5% CO2 at
37uC.
Gene Silencing
Control and Praf2-targeting siRNA oligonucleotides were from
Qiagen. The sequences used (only sense sequences given) were:
Praf2 siRNA5, 59-CCAGGUCAAGACAUUGCCAAAdTdT-39;
Praf2 siRNA6, 59-GUGUUGCUGCAACAAUAAAdTdT-39.
siRNAs were transfected with the ‘‘fast-forward’’ protocol using
HiPerFect (Qiagen) as transfection reagent. Briefly, 2610
5 cells/
well were seeded in 6-well plates and incubated with the
transfection complexes (20 nM siRNA and 12 ml of HiPerFect in
cell growth medium). After 48–72 hours cells were processed.
Western blotting
Whole cells or membrane fractions were lysed in CHAPS
Extraction Buffer (CEB) [50 mM Tris/Hcl pH 8.0, 150 mM
NaCl, 5% glycerol, 1% CHAPS, 2 mM EGTA, 1 mM DTT,
16Complete
TM (Roche)]. After 15 min incubation on ice, lysates
were cleared by centrifugation. Total cell extracts were separated
on 10% or 12.5% SDS-PAGE and transferred to Immobilon-P
transfer membranes (Millipore). After blocking with 5% non-fat
milk membranes were incubated with primary antibodies as
recommended by the supplier. The immune complexes were
detected by the ECL detection system according to the manu-
facturer’s protocol (Millipore).
Sucrose gradients
12610 cm
2 confluent dishes of U2OS cells were collected by
trypsinisation, washed with PBS and resuspended in 1.5 ml of
CHAPS Extraction Buffer (CEB) [50 mM Tris/Hcl pH 8.0,
150 mM NaCl, 5% glycerol, 1% CHAPS, 2 mM EGTA, 1 mM
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TM (Roche)]. Lysates were cleared by
centrifugation (15 min at 13200 rpm) and 1 ml was loaded on
the top of a step gradient obtained by layering 2 ml of each of the
following sucrose solutions: 40 - 32.5 – 25 - 17.5 and 10% sucrose
in 50 mM Tris/Hcl pH 8.0, 150 mM NaCl, 1% CHAPS, 2 mM
EGTA, 1 mM DTT. The gradient was centrifuged at 35.000 rpm
for 22 hours in a SW41 rotor (Beckman), with break at position
zero. 60 fractions (4 drops/fraction) were collected from the
bottom of the tube after piercing the tube with a hot needle. Equal
volumes (30 ml) of eve numbers fractions were analysed by
Western blotting as described.
Subcellular fractionation
4610 cm
2 confluent dishes of HeLa/TAP-Bcl-xL were collected
by trypsinisation, washed with PBS and resuspended in HS buffer
(10 mM HEPES pH7.4, 250 mM sucrose, 16Complete
TM). Cells
were lysed by Dounce homogenisation (30 strokes, pestle B) and
centrifuged 10 min at 6006g to pellet the nuclear fraction (Nuclei).
The supernatant was centrifuged 15 min at 9,0006g to pellet the
heavy membrane fraction (HMM). The supernatant was centri-
fuged 30 min at 100,0006g to pellet the light membrane fraction
(LMM). The final supernatant was taken as S100 fraction. Nuclei,
HMM and LMM pellets were resuspended in CHAPS Extraction
Buffer (CEB) [50 mM Tris/Hcl pH 8.0, 150 mM NaCl, 5%
glycerol,1%CHAPS,2 mMEGTA,1 mMDTT,16Complete
TM
(Roche)] and equal amount of proteins were analysed by Western
blotting as described above.
Generation of TAP-Bcl-xL expressing cells and Tandem
Affinity Purification
A pcDNA3 based expression construct designed to fuse the TAP
tag with an optimised TEV cleavage consensus sequence to the N-
Terminus of Bcl-xL was created. The construct had in series: a
Kozak initiation site, a 3 Gly spacer, 2 IgG tags, a TEV spacer
(DYDIPTT) and a TEV cleavage site (ENLYFQ*G), a 5 Gly
spacer, a CBP tag and a 6 Gly spacer. A control construct was
created by inserting a stop codon after the TAP tag sequence.
After electroporation, HeLa cells clones stably expressing the
fusion protein or the TAP alone, were selected using 0.8 mg/ml of
G418.
TAP purifications were performed as previously describe [28]
with some modifications. Briefly, HeLa cells expressing TAP-Bcl-
xL or TAP-stop were adapted to grow in supension in glass
spinning bottles. Cell pellets from 1.5–2 liters of cultures were
lysed on ice by dounce homogenization in 10 ml of HS buffer
(10 mM HEPES pH7.4, 250 mM sucrose, 16 Complete
TM).
Total membranes where isolated by centrifugation (160006g for
30 mins) and extracted with 10 ml of CHAPS Extraction Buffer
(CEB) [50 mM Tris/Hcl pH 8.0, 150 mM NaCl, 5% glycerol, 1%
CHAPS, 2 mM EGTA, 1 mM DTT, 16Complete
TM (Roche)].
The clarified membrane extract was incubated with 600 mlo fa
50% suspension of pre-washed IgG-linked agarose (Sigma) for
2 hrs at 4uC with rotation. The agarose matrix was then washed
with 30 ml of CEB and 10 ml of TEV cleavage buffer (10 mM
Tris HCl pH 8.0, 150 mM NaCl, 0.1% CHAPS, 0.5 mM EDTA,
1 mM DTT). The agarose matrix was then incubated with 950 ml
TEV cleavage buffer and 500 U TEV protease (Invitrogen) for
2 hrs at RT, followed by O/N at 4uC with rotation. The resulting
eluate was supplemented with 3.5 ml calmodulin binding buffer
(10 mM Tris HCl pH 8.0, 150 mM NaCl, 0.1% CHAPS, 1 mM
Mg acetate, 1 mM imidazole, 2 mM CaCl2, 10mM BME) and
3.5 ml 1 M CaCl2 and incubated with 500 ml of a 50% suspension
of Calmodulin-linked affinity resin (Stratagene) for 4 hrs at 4uC
with rotation. The Calmodulin resin was washed 30 ml of binding
buffer and the bound proteins eluted with 56200 ml fractions of
calmodulin elution buffer (2 mM CaCl2 was substituted for 2 mM
EGTA). TAP eluates were concentrated using Microcon YM-10
columns (Millipore) to a final volume of ,30 ml and purified
proteins visualized on 4–12% NuPAGE gels (Invitrogen) using
colloidal coomassie (Sigma).
Mass spectrometry
Bands corresponding to the most abundant protein species were
excised from SDS PAGE gels and digested with 16 Units Porcine
trypsin (Promega) according to the manufacturer’s instructions.
Peptides were extracted 3 times with 30 ml 5% formic acid, dried
in a SpeedVac and desalted. Immediately prior to analysis
peptides were resuspended in 7 ml 1% formic acid and 5 ml
injected onto a nano HPLC system (LC Packings) with 75 mm
I.D.6150 mm column packed with Vydac C18 (5 mm particles).
Separation was achieved using a flow rate of 250 nl/min (gradient
0% to 95% of 0.1% acetic acid in acetonitrile) and eluted peptides
were analyzed directly by tandem electrospray mass spectrometry
using either a qTOF (Micromass) or ABI 4000 QTRAP MS/MS
System (Applied Biosystems). The resulting mass spectra were
queried against the NCBI non-redundant database using the
Mascot software (Matrix Science). One missed cleavage per
peptide and an initial mass tolerance of 10 ppm were used in all
searches.
Immunoprecipitations
HEK 293T cells (1610
5/35cm
2 dishes) were transfected using
Polyfect as transfection reagent (Qiagen). After 24 hours cells were
scraped on dish, washed with PBS and lysed in 500 ml of CEB
[50 mM Tris/Hcl pH 8.0, 150 mM NaCl, 5% glycerol, 1%
CHAPS, 2 mM EGTA, 1 mM DTT, 16Complete
TM (Roche)].
Lysates were cleared at 13000 rpm for 15 min and therefore
incubated with 20 ml of anti HA conjugated Agarose (Sigma),
previously equilibrated in CEB, for 2 hours at 4uC, rotating.
Agarose was washed 3 times with 1 ml of CEB, resuspended in
30 mlo f2 6Laemmli buffer and boiled 5 min. Equal volumes of
supernatants were resolved on 12% SDS-PAGE and analysed by
Western blot.
For the immunoprecipitation of endogenous Bcl-xL from U2OS
cells, 2610 cm
2 dishes of 60% confluent U2OS were transfected
using Effectene (Qiagen) with 2 mg of either empty
pcDNA3C3xHA or pcDNA3C3xHA/Praf2. After 24 hours cells
are extracted with 800 ml of CEB and cleared by centrifugation.
560 mg of protein extracts were incubated with 20 ml of anti HA
conjugated Agarose (Sigma), previously equilibrated in CEB, for
2 hours at 4uC, rotating. Agarose was washed 3 times with 1 ml of
CEB, resuspended in 30 mlo f2 6 Laemmli buffer and boiled
5 min. Equal volumes of supernatants were resolved on 12% SDS-
PAGE and analysed by Western blot.
Cell viability assays
Caspase-3 and -7 activities were measured by using a Caspase-
Glo 3/7 Assay kit (Promega). Experiments were carried out
following manufacturer’s recommended procedures. Briefly,
5610
3 of U2OS cells/well were plated in white-walled 96-well
plates and transfected the same day with 20 nM of the indicated
siRNAs using HiPerfect (Qiagen). After treating the cells as
specified in figure legends, the Caspase-Glo 3/7 reagent was
added to the wells followed by measurements of luminescence 1 h
later with a plate-reading luminometer (GloMaxH 96 Luminom-
eter, Promega). To measure clonogenicity, U2OS cells were
transfected with control or Praf2 targeting siRNAs as specified
above and after 24 hours plated in 10 cm
2 dishes in triplicate at
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etoposide 50 mM for 3 hours and then medium was changed. Cells
were grown for 10–15 days and colonies were stained using crystal
violet.
Immunofluorescence
U2OS cells, plated on glass coverslips were co-transfected with
GFP-Bax and 3xHA-Praf2 or the empty vector using Effectene
(Qiagen) as transfection reagent. After 22 hours cells were fixed in
4% paraformaldehyde in PBS for 10 min at room temperature
and washed three times in PBS. Paraformaldehyde was quenched
with 10 mmol/L ammonium chloride, and cells were permeabi-
lized with PBS, 0.1% Triton X-100 for 5 min at room
temperature. The coverslips were washed three times in PBS
and then blocked in PBS, 0.5% bovine serum albumin for 30 min.
Cells were incubated with anti HA monoclonal antibody diluted in
PBS, 0.5% bovine serum albumin for 1 h at room temperature.
Coverslips were washed five times in PBS and treated for 1 h at
room temperature with the secondary anti mouse antibody
AlexaFluor 594 (Invitrogen) diluted in PBS, 0.5% bovine serum
albumin. Coverslips were washed in PBS and mounted with
ProLong Gold anti fade reagent with DAPI (Invitrogen). The cells
were visualized by fluorescence microscopy (Leica DM6000).
Supporting Information
Figure S1 Analysis of the expression levels of TAP-Bcl-
xL, Bcl-xL and Praf2 in HeLa-TAP-Bcl-xL and U2OS
cells. Equal amount of total cell lysates were resolved on SDS-
PAGE and analysed by Western blotting using the antibodies
indicated. Tubulin was used as loading control.
(TIF)
Figure S2 Praf2 knock down reduces chemotherapy-
induced apoptosis in U2OS and MDA-MB 231cells. (A)
Praf2 RNAi in U2OS reduces apoptosis induced also by paclitaxel
and doxorubicin. Cells were transfected with control or Praf2
targeting siRNAs. After 48 hours cells were treated for 24 hours
either with 100 nM paclitaxel (Sigma) or 0.5 mg/ml doxorubicin
(Sigma). (B) Praf2 RNAi reduces etoposide-induced apoptosis also
in MDA-MB 231cells. Cells were transfected with control or Praf2
targeting siRNAs. After 48 hours cells were treated for 24 hours
with 50 mM etoposide. Cellular caspase 3 and 7 activities were
measured using the Caspase-Glo 3/7 luminometric assay. The
graph show the percentage of caspase 3 and 7 activation in
samples treated with the Praf2 targeting siRNAs compared with
the activity present in cells transfected with the control siRNA in 2
independent experiments.
(TIF)
Figure S3 Praf2 partially co-localises with Bcl-xL in
U2OS cells. U2OS cells were transfected with HA-Praf2 and
analysed by confocal immunofluorescence microscopy using an
antibody directed against Bcl-xL (Pharmingen) and an antibody
recognising the HA-tag (Sigma).
(TIF)
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